AC Immune Income Statement (2015-2026) | ACIU

Income Statement Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
4.04M0.76M29.41M1.30M1.10M1.58M1.17M0.42M1.43M
Operating items
Depreciation & Amortization - Total (Quarter)
Research & Development (Quarter)
-15.04M-16.47M-21.82M-16.38M-16.29M-14.90M-15.71M-15.00M-15.22M-14.05M-16.51M-17.37M-18.95M-16.72M-18.02M-17.70M-20.32M-16.34M-13.29M-15.00M
Share-based Compensation (IS) (Quarter)
0.43M
Selling, General & Administrative (Quarter)
-5.74M-5.90M-3.16M-4.51M-4.54M-3.39M-4.11M-4.44M-4.09M-3.92M-4.57M-5.70M-5.03M-4.33M-4.55M-4.94M-4.71M-4.46M-5.25M-5.33M
Restructuring Costs (Quarter)
-0.58M0.02M
Other Operating Expenses (Quarter)
0.28M0.28M0.28M0.50M0.21M0.27M0.41M0.44M0.35M0.46M0.40M0.08M0.05M0.02M0.02M-0.00M0.03M0.09M0.01M
Operating Expenses (Quarter)
-20.50M-22.09M-24.71M-20.39M-20.62M-18.01M-19.41M-19.00M-18.96M-17.51M-20.68M-22.99M-23.94M-21.03M-22.55M-22.65M-25.00M-21.38M-18.43M-20.31M
Operating Income (Quarter)
-20.50M-22.09M-24.71M-20.39M-20.62M-13.94M-19.41M-19.00M-18.96M-17.51M-3.99M-22.99M-23.18M8.39M-21.25M-21.54M-23.42M-20.21M-18.01M-18.88M
EBIT (Quarter)
-20.50M-22.09M-24.71M-20.39M-20.62M-13.94M-19.41M-19.00M-18.96M-17.51M-3.99M-22.99M-23.18M8.39M-21.25M-21.54M-23.42M-20.21M-18.01M-18.88M
Non-operating items
Interest & Investment Income (Quarter)
4.82M12.41M-0.19M-0.44M0.01M0.06M0.23M0.29M0.32M0.33M-2.37M0.82M1.08M1.01M0.76M0.55M0.46M0.44M0.29M
Other Non Operating Income (Quarter)
-0.20M0.13M-0.41M0.15M0.36M0.02M-0.11M-0.06M-0.02M0.08M-1.65M1.85M-2.77M-3.08M2.24M-0.32M-2.67M-0.02M-0.36M-0.22M
Non Operating Income (Quarter)
-0.42M4.75M1.64M-0.02M0.23M-0.05M-0.05M0.07M0.24M0.37M-1.36M2.53M-1.99M-2.04M-1.16M0.38M-2.18M0.39M2.44M-0.02M
Net income details
EBT (Quarter)
-20.91M-17.34M-23.07M-20.40M-20.39M-13.99M-19.46M-18.93M-18.72M-17.14M-5.35M-20.46M-25.17M6.35M-18.03M-21.17M-25.59M-19.82M-17.98M-18.90M
Tax Provisions (Quarter)
-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M
Profit After Tax (Quarter)
-20.91M-17.34M-23.07M-20.41M-20.40M-14.00M-19.46M-18.93M-18.72M-17.14M-5.35M-20.46M-25.17M6.35M-18.03M-21.17M-25.59M-19.82M-17.98M-18.90M
Income from Continuing Operations (Quarter)
-20.91M-17.34M-23.07M-20.40M-20.39M-13.99M-19.46M-18.93M-18.71M-17.14M-5.35M-20.46M-25.17M6.35M-18.03M-21.17M-25.59M-19.82M-17.98M-18.90M
Consolidated Net Income (Quarter)
-20.91M-17.34M-23.07M-20.40M-20.39M-13.99M-19.46M-18.93M-18.71M-17.14M-5.35M-20.46M-25.17M6.35M-18.03M-21.17M-25.59M-19.82M-17.98M-18.90M
Income towards Parent Company (Quarter)
-20.91M-17.34M-23.07M-20.40M-20.39M-13.99M-19.46M-18.93M-18.71M-17.14M-5.35M-20.46M-25.17M6.35M-18.03M-21.17M-25.59M-19.82M-17.98M-18.90M
Net Income towards Common Stockholders (Quarter)
-20.91M-17.34M-23.07M-20.40M-20.39M-13.99M-19.46M-18.93M-18.71M-17.14M-5.35M-20.46M-25.17M6.35M-18.03M-21.17M-25.59M-19.82M-17.98M-18.90M
Additional items
EPS (Basic) (Quarter)
-0.01-0.01-0.24-0.01-0.01-0.22-0.01-0.01-0.01-0.06-0.01-0.010.00-0.01-0.01-0.01-0.01-0.14
EPS (Weighted Average and Diluted) (Quarter)
0.00M
Shares Outstanding (Weighted Average) (Quarter)
1,687.74M1,730.63M97.28M1,943.64M1,864.77M86.73M1,942.85M2,001.92M2,040.14M95.48M2,397.91M2,446.02M2,560.03M2,541.03M2,480.32M2,700.84M2,800.25M127.30M
Shares Outstanding (Diluted Average) (Quarter)
EBITDA (Quarter)
-20.50M-22.09M-24.71M-20.39M-20.62M-13.94M-19.41M-19.00M-18.96M-17.51M-3.99M-22.99M-23.18M8.39M-21.25M-21.54M-23.42M-20.21M-18.01M-18.88M
Interest Expenses (Quarter)
-0.22M-0.20M-0.19M-0.17M-0.13M-0.08M-0.73M0.10M-0.03M-0.03M-0.37M-0.04M-0.04M-0.04M0.27M-0.06M-0.06M-0.06M-0.05M-0.08M
Tax Rate (Quarter)
0.02%0.02%0.03%0.01%0.02%0.02%0.02%0.02%